HAOHAI BIOTEC acquires 19.8% of Ruiji Bio for a consideration of 38.35 million RMB
HAOHAI BIOTEC (06826.HK) announced the acquisition of a 19.8% stake in Ruiji Biotech from an independent third party. The latter's products are mainly used in the fields of orthopedics and ophthalmology, with a cash consideration of RMB 38.35 million, which will be paid using internal resources
Source: AASTOCKS The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments